COPD: frequent exacerbations, high-dose steroids tied to T2DM

  • Gayle A & al.
  • NPJ Prim Care Respir Med
  • 15 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • COPD is associated with a higher incidence of type 2 diabetes mellitus (T2DM).
  • The elevated risk is associated with exposure to high-dose inhaled corticosteroids (ICS) and frequent COPD exacerbations.

Why this matters

  • Clinicians should aggressively monitor for T2DM among patients with COPD using ICS and having frequent COPD exacerbations.

Study design

  • Nested case-control within large retrospective primary care cohort, the Clinical Practice Research Datalink (n=220,971 with COPD).
  • 20,488 cases with incident T2DM were compared with 200,483 controls without T2DM matched 1:5 by age, sex, and general practitioner practice.
  • Funding: Boehringer Ingelheim Ltd.

Key results

  • Among the larger cohort (n=220,971), the incidence of T2DM in patients with COPD was 1.26 (95% CI, 1.24-1.28) per 100 patient years, with the rate being higher among men (1.32 vs 1.18 in women).
  • The nested case-control found:
    • Adjusted OR for incident T2DM, 1.47 (95% CI, 1.36-1.60) among patients with frequent exacerbations (≥2 treated exacerbations per year vs infrequent exacerbations).
    • Adjusted OR for incident T2DM, 1.73 (95% CI, 1.65-1.82) among patients receiving high-dose ICS (>800 mcg budesonide equivalent dose vs no ICS).

Limitations

  • Retrospective observational cohort.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit